SARS‑CoV‑2 RNA (COVID‑19) and Respiratory Pathogen Panel, Qualitative NAAT
Also known as: Parainfluenza, Novel Coronavirus, Adenovirus, Wuhan, COVID19
Use
This qualitative NAAT enables simultaneous detection of SARS‑CoV‑2 (COVID‑19) and a broad range of respiratory pathogens from a single specimen, facilitating differential diagnosis of respiratory infections and guiding early treatment decisions. This approach improves diagnostic efficiency, reduces patient discomfort, and aids antimicrobial stewardship by distinguishing viral etiologies, including viruses and bacterial pathogens that present with similar symptoms.
Special Instructions
This panel uses a single test code (31687) and requires only one patient specimen. Cotesting simplifies ordering and reduces specimen collection burden. Ordering components separately is also possible via individual test codes for each pathogen panel.
Limitations
Authorized under FDA EUA for simultaneous qualitative detection only; not FDA cleared or approved. Authorization limited to declared emergency period and restricted to specified pathogens; does not cover pathogens beyond those listed. Differentiation is qualitative; does not quantify pathogen load.
Methodology
NGS
Biomarkers
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Not provided.